CNSP - CIK 0001729427
The table below shows CNS Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.95M | $9.86M | $12.13M | $13.05M | $6.97M | $1.49M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.08M |
| $11.39M |
| $14.14M |
| $13.72M |
| $7.39M |
| $2.15M |
| Property, plant & equipment | $22.01K | $3.11K | $3.80K | $4.91K | $2.80K | $3.55K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $4.65M | $11.87M | $14.51M | $13.75M | $7.41M | $2.47M |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $4.58M | $1.96M | $1.38M | $2.78M | $4.06M | $6.76M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $4.58M | $1.96M | $1.38M | $2.78M | $4.06M | $6.76M |
| Retained earnings | -$105.21M | -$94.32M | -$91.10M | -$88.73M | -$81.25M | -$75.64M |
| Total equity | $70.70K | $9.91M | $13.12M | $10.97M | $3.35M | -$4.29M |